April 5 (Reuters) – Novavax Inc:

* NOVAVAX INITIATES COVID-19 VACCINE CLINICAL TRIAL CROSSOVER

* NOVAVAX INC – CROSSOVER ALLOWS PARTICIPANTS TO CONTINUE IN TRIALS AND REMAIN BLINDED

* NOVAVAX INC – CROSSOVER ENSURES THAT ALL TRIAL PARTICIPANTS RECEIVE ACTIVE VACCINE

* NOVAVAX INC – SOUTH AFRICA AND UK CROSSOVER ARMS INITIATED; US/MEXICO PREVENT-19 CROSSOVER PLANNED

* NOVAVAX INC – ALL PARTICIPANTS IN UK AND U.S. PHASE 3 TRIALS WILL BE OFFERED OPPORTUNITY TO RECEIVE AN ADDITIONAL ROUND OF INJECTIONS

* NOVAVAX – PLANNING TO EXPAND TRIAL TO INCLUDE PEDIATRIC AND ADOLESCENT ARMS, WHICH ARE ALSO EXPECTED TO BEGIN IN Q2

Advertisement

* NOVAVAX INC – COMPANY IS ALSO PLANNING A CROSSOVER IN PREVENT-19 STUDY, FOR WHICH COMPANY EXPECTS TO READ OUT INITIAL CLINICAL DATA DURING Q2 Source text for Eikon: Further company coverage:

(c) Copyright Thomson Reuters 2021. Click For Restrictions – https://agency.reuters.com/en/copyright.html